SNSS Financial Facts

Research and development: 6.94M
Total operating expenses: 14.17M
See Full Income Statement

Total liabilities and stockholders' equity: 46.05M
Additional paid-in capital: 524.99M
See Full Balance Sheet

Sunesis Pharmaceuticals Inc. (SNSS) Earnings

  |   Expand Research on SNSS
Next EPS Date 3/6/15 *Est. EPS Growth Rate -56.3% *Last Qtr.
Average EPS % Beat Rate -23.2% Revenue Growth Rate -57.1% *Last Qtr.
Average % Move 1-Wk after EPS +1.5% Normal Earnings Time Before Open
Date  Qtr EPS Cons. Surprise Revs Cons. Gd. 1-Week % 1-Day % Details
11/10/14 Q314 -$0.25-$0.17 -$0.08$854K$1.97M N/A Details
8/5/14 Q214 -$0.20-$0.17 -$0.03$2M$1.32M N/A Details
5/7/14 Q114 -$0.26-$0.17 -$0.09$2M$1.32M N/A Details
3/6/14 Q413 -$0.15-$0.20 +$0.05$2M$1.37M N/A Details
11/12/13 Q313 -$0.16-$0.20 +$0.04$1.99M$1.44M N/A Details
7/29/13 Q213 -$0.18-$0.21 +$0.03$1.99M$1.22M N/A Details
5/9/13 Q113 -$0.23-$0.20 -$0.03$1.99M$750K N/A Details
3/13/13 Q412 -$0.20-$0.19 -$0.01$1.99M$320K N/A Details